Tanshinone IIA is a compound purified from the Chinese herb Danshen (Radix Salviae Miltiorrhiza Bge). The neuroprotective effect of tanshinone IIA was investigated in a neonatal rat model of hypoxia-ischemia brain damage. Hypoxia-ischemia encephalopathy was induced in rats at day 7 of postnatal age by ligation of the right common carotid artery, followed by 2 h of hypoxia. Tanshinone IIA (10 mg/kg, i.p.) was injected daily from day 2 before surgery for 9 or 16 d. Our results demonstrated significant and sustained brain damage in the hypoxia-ischemia-and vehicle-treated groups at 1 and 3 wk after surgery. Treatment with tanshinone IIA significantly reduced the severity of brain injury, as indicated by the increase in ipsilateral brain weight and neuron density, compared with those of sham-operated animals. The recovery of sensorimotor function and histology was observed in animals that received tanshinone IIA. The plasma of tanshinone IIA-treated rats exhibited higher antioxidant activities, as reflected by the oxygen radical absorbance capacity assay, compared with the vehicle-treated rats. In the neural progenitor cell line C17.2 that was subjected to 2,2'-azobis (2-amidino propane hydrochloride)-induced oxidative stress, tanshinone IIA increased cell viability and protected against mitochondrial damage (JC-1 assay). Our results suggest that tanshinone IIA has antioxidative activities and that treatment that is started before a hypoxic-ischemic insult is partially neuroprotective. Further studies are required to elucidate whether rescue treatment with tanshinone IIA is effective and to determine whether its protective effect is also associated with secondary cooling of the brain. Abbreviations AAPH, 2,2'-azobis (2-amidino propane hydrochloride) AchE, acetylcholinesterase HIE, hypoxia-ischemia encephalopathy MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide NSE, neuron-specific enolase ORAC, oxygen radical absorbance capacity Hypoxia-ischemia encephalopathy (HIE) in the newborn infant is a major cause of acute mortality and chronic neurologic disability in survivors. During hypoxic-ischemic brain injury, mitochondrial functions are compromised and the lack of electron acceptors leads to free radical leakage from the mitochondria into the cytoplasm, causing lipid peroxidation of polyunsaturated fatty acid-rich neuronal membranes (1,2).
Tanshinone IIA is a compound purified from the Chinese herb Danshen (Radix Salviae Miltiorrhiza Bge). The neuroprotective effect of tanshinone IIA was investigated in a neonatal rat model of hypoxia-ischemia brain damage. Hypoxia-ischemia encephalopathy was induced in rats at day 7 of postnatal age by ligation of the right common carotid artery, followed by 2 h of hypoxia. Tanshinone IIA (10 mg/kg, i.p.) was injected daily from day 2 before surgery for 9 or 16 d. Our results demonstrated significant and sustained brain damage in the hypoxia-ischemia-and vehicle-treated groups at 1 and 3 wk after surgery. Treatment with tanshinone IIA significantly reduced the severity of brain injury, as indicated by the increase in ipsilateral brain weight and neuron density, compared with those of sham-operated animals. The recovery of sensorimotor function and histology was observed in animals that received tanshinone IIA. The plasma of tanshinone IIA-treated rats exhibited higher antioxidant activities, as reflected by the oxygen radical absorbance capacity assay, compared with the vehicle-treated rats. In the neural progenitor cell line C17.2 that was subjected to 2,2'-azobis (2-amidino propane hydrochloride)-induced oxidative stress, tanshinone IIA increased cell viability and protected against mitochondrial damage (JC-1 assay). Our results suggest that tanshinone IIA has antioxidative activities and that treatment that is started before a hypoxic-ischemic insult is partially neuroprotective. Further studies are required to elucidate whether rescue treatment with tanshinone IIA is effective and to determine whether its protective effect is also associated with secondary cooling of the brain. Hypoxia-ischemia encephalopathy (HIE) in the newborn infant is a major cause of acute mortality and chronic neurologic disability in survivors. During hypoxic-ischemic brain injury, mitochondrial functions are compromised and the lack of electron acceptors leads to free radical leakage from the mitochondria into the cytoplasm, causing lipid peroxidation of polyunsaturated fatty acid-rich neuronal membranes (1, 2) .
Danshen is derived from the dried root or rhizome of Salviae Miltiorrhizae Bge. In recent decades, Danshen has been commonly used in China for the treatment of angina pectoris and cerebrovascular disorders such as ischemic stroke (3). Tanshinone IIA, a derivative of phenanthrenequinone, is one of the key components of Danshen (Fig. 1) . It has antioxidant properties and has been demonstrated to protect against lipid peroxidation in in vitro and in vivo studies (4, 5) . Tanshinone IIA can prevent the neuroblastoma cell line PC12 from apoptosis induced by serum-free culture conditions (6) . It has the potential to penetrate the blood-brain barrier and acts as an inhibitor of acetylcholinesterase (AchE) (7). These observations prompted us to speculate that tanshinone IIA may protect against HIE in neonates. In the present study, we investigated the neuroprotective effect of tanshinone IIA on a validated xylazine (0.01 mg/kg) and then transcardially infused with 0.9% saline followed by 10% ice-cold neutral formaldehyde (Sigma Chemical Co.). Their brains were removed, placed in 10% neutral formaldehyde overnight at room temperature, and processed for paraffin histology. Five-micrometer sections were cut and deparaffinized in xylene and graded alcohol before they were immersed in citrate buffer (pH 7.6) for antigen retrieval in a microwave oven. The sections were placed in 3% hydrogen peroxide for 20 min to block endogenous peroxidase and then incubated in 5% rabbit serum (Dako, Glostrup, Demark) for 10 min. The primary MAb against neuron-specific enolase (NSE; 1:400 dilution; Calbiochem, Darmstadt, Germany) (8) was added onto the sections, which then were incubated overnight at room temperature. The sections were treated further with a biotinylated rabbit antimouse antibody (1:1000 dilution; Dako) for 40 min before incubation with horseradish peroxidase (HRP; Zymed, San Francisco, CA) for 45 min. Color development was performed in 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemical Co.) solution for 10 min. After staining, the sections were washed and coverslipped with Permount (Fisher Scientific, Loughborough, UK).
Counting of cortical neurons in the sensorimotor area of the forelimb. The number of cortical neurons in the sensorimotor area of the forelimb (9) were counted in five randomly selected frontal sections by an investigator who was blinded to the allocation of treatment groups. These neurons were identified by their location, size, and NSE staining. The neuron density of each group (three rats) was expressed as the mean number of neurons per 10,000 m 2 .
Functional test. A standard postural reflex test was performed to evaluate the extent of neural recovery in rat pups 3 wk after surgery (10) . The investigator had no previous information on the treatment group of the rats. The pup (sham-operated group n ϭ 23; vehicle-treated group n ϭ 26; tanshinone IIA-treated group n ϭ 27) was held by the tail 50 cm above a table. Normal rat pups extended both forelimbs toward the table (score 0). Pups with brain damage flexed the forelimb contralateral to the damaged hemisphere (score 1). The pup then was put onto the table, and a lateral pressure was applied behind the shoulder until the forelimbs slid. A reduced resistance to this lateral force toward the left side (contralateral to the brain damage) was considered abnormal (score 2). Results are presented as the percentage of rats in each of the functional groups.
Body temperature measurement. In an independent experiment, daily rectal temperature was measured in the three treatment groups of neonatal rats, using a Bioprober temperature sensor (0.7 mm diameter) connected directly to the Powerlab/16S system (AD Instruments Pty Ltd, Victoria, Australia), and data were analyzed by the Powerlab Chart V4.2 software. The unrestrained pups were acclimatized inside an infant incubator (Air-shields-C100; Narco Scientific, Hatboro) at 32°C for 30 min before their rectal temperatures were recorded (11) .
Oxygen radical absorbance capacity assay. With the use of the same peroxyl radical generator for both lipophilic and hydrophilic antioxidants, ORAC levels were measured in the plasma of rat pups 2 wk after surgery (12) . Ten pups were randomly selected from each treatment group. Peripheral blood samples were collected from the left heart ventricle. They were centrifuged at 10,000 ϫ g for 10 min at 4°C. Total ORAC in plasma was measured as described by Wang et al. Ten L 2,2'-azobis (2-amidinopropane) hydrochloride (160 mM; AAPH; Sigma Chemical Co.) was added to a reaction mixture of 300 L of ␤-phycoerythrin (3.8 mg/L; Sigma Chemical Co.) and 20 L of Trolox (range 0 -100 M; Sigma Chemical Co.) or whole plasma (1:200 dilution) and incubated in a dual-scanning spectrofluorometer (Gemini SpectraMAX; Molecular Devices, Tokyo, Japan) at 37°C. The phycoerythrin fluorescence decay was monitored at 2-min intervals for 70 min at 546 nm excitation and 565 nm emission. ORAC values were calculated according to the area under the curve using the SOFTmax PRO software (Molecular Devices, Tokyo, Japan) and expressed as the equivalence of 1 M Trolox.
Effects of tanshinone IIA on C17.2 cell viability. The mouse neural progenitor cell line C17.2 was cultured in IMDM (GIBCO, CA) supplemented with 10% (vol/vol) FCS (GIBCO) in an atmosphere of 5% CO 2 /95% humidified air at 37°C. AAPH was prepared as a stock solution (100 mg/mL) in IMDM and diluted to a 4-mg/mL working solution immediately before use. C17.2 cells (5 ϫ 10 3 /well) were seeded in a 96-well plate. After being cultured in IMDM with 10% FCS overnight, the cells were washed twice with PBS and then incubated with AAPH at 4 mg/mL in serum-free IMDM. In the vehicletreated and tanshinone IIA-treated cultures, the vehicle and tanshinone IIA at different doses (0, 0.02, 0.05, 0.1, and 0.2 g/mL) were added. After 8 h of incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution (5 mg/mL, 20 L per well) was added. After 4 h, the supernatant was discarded and DMSO (200 L) was added to each well. The suspension was placed on a micro-vibrator for 5 min, and the absorbance (A) was measured at 570 nm with a microplate spectrophotometer (-Quant Microplate Spectrophotometer; Bio-tek, Instruments Inc., Winooski, VT). Cell 
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TANSHINONE IIA NEUROPROTECTIVE EFFECT viability relative to the control culture (without AAPH) was calculated by the formula (absorbance of treated sample/absorbance of control sample) ϫ 100%.
Effects of tanshinone IIA on mitochondrial integrity. Mitochondrial integrity was assessed by monitoring the mitochondrial membrane potential changes using the ApoAlert Mitochondrial Membrane Sensor Kit (BD Clontech, Palo Alto, CA) according to the manufacturer's instructions. JC-1 is a membrane-permeable lipophilic cation fluorescent indicator that is specifically accumulated in the mitochondria as a result of a negative interior potential. The loss of this membrane potential causes shifts in fluorescence emission from red (aggregates) to green (monomers). C17.2 cells in IMDM cultures that contained 10% FCS were subjected to oxidative stress (AAPH, 4 mg/mL) and treated with 0 or 0.1 g/mL tanshinone IIA. After 8 h, 1 ϫ 10 6 cells were incubated with 1 mL of diluted JC-1 for 15 min at 37°C in a 5% CO 2 incubator. The cells then were washed with 1 mL of incubation buffer and resuspended in 1 mL of buffer. The monomers and aggregates of JC-1 were detected at the FL1 and FL2 channels, respectively.
Statistical analysis. The data are expressed as means Ϯ SD. Results from in vivo studies were compared by one-way ANOVA. 
RESULTS

Mortality.
The mortality rates of pups in the vehicle-treated and tanshinone IIA-treated groups were 11.0 and 12%, respectively. These pups died during either surgery or hypoxia. All surviving pups in the three treatment groups did not display differences in their total body weights, with mean range of 23.3-24.4 g at 1 wk and 96.4 -100 g at 3 wk after surgery. No discernible physiologic and behavioral changes as a result of intoxication were observed.
Brain weight. At both assessment time points of 1 and 3 wk after hypoxia-ischemia treatment, pups in the vehicle group had decreased weights of the ipsilateral hemisphere (hypoxiaischemia side), compared with those in the sham-operated group (p Ͻ 0.05; Table 1 ). Pups that were treated with tanshinone IIA for 9 or 16 d had significantly heavier right brain weights and less brain damage (p Ͻ 0.05) in comparison with those of the vehicle group. Similar effects were observed in the total brain weight at 3 wk after surgery (p Ͻ 0.05). The contralateral brain weights of all groups were similar at both time points. The recovery, however, remained incomplete as demonstrated by the 13.2 and 11.5% reduction of the relative brain weights at 1 and 3 wk, respectively (p Ͻ 0.05, tanshinone IIA versus sham-operated).
Cerebral cortical atrophy. Examination of the external morphology of the brain at 3 wk after the hypoxia-ischemia treatment demonstrated that whereas the sham-operated pups had normal brain size and hemispheric morphology ( Fig. 2A), severe atrophy of the right brain occurred in the vehicle-treated animals (Fig. 2B) . Tanshinone IIA treatment reduced the extent of atrophy, and the right hemisphere almost returned to its normal size and morphology (Fig. 2C) . Coronal sections through the striatum showed that sham-operated pups had normal brain histology (Fig. 2D) , whereas vehicle-treated pups that were subjected to hypoxia-ischemia had brain damage at varying extents, ranging from slight neuronal loss to a marked degeneration of the ipsilateral hemisphere (Fig. 2E) . Cell death and necrotic nuclei were found scattered in the cerebral cortex, and the degenerative change was especially obvious in the outer layer of the cerebral cortex. Treatment with tanshinone IIA resulted in a remarkable reduction in the severity of injury (Fig. 2F) . The neuronal damage was moderate, compared with those of the vehicle group. The hemispheric structure seemed intact, with the only abnormality being the slight reduction in size.
Cortical neurons by NSE staining. At 3 wk after surgery, the number of cortical neurons in the sensorimotor area of the forelimb in the ipsilateral hemisphere of the vehicle-treated animals was significantly decreased in comparison with that of the sham-operated group (p Ͻ 0.05; Figs. 2G and H and Fig.  3 ). Treatment with tanshinone IIA significantly increased the number of neurons (p Ͻ 0.05; Figs. 2H and I and Fig. 3 ), although it remained significantly less than that of the shamoperated pups (p Ͻ 0.05; Fig. 3 ). The numbers of cortical neurons in the contralateral hemispheres were similar in the three treatment groups.
Postural reflex test. All sham-operated animals obtained score 0, and none of them had abnormal postural responses of score 1 and score 2 (Fig. 4) . The vehicle-treated pups demonstrated abnormal postural responses to the reflex test, and significant numbers of them were classified in scores 1 and 2 (p Ͻ 0.05). Some animals in this group displayed normal postural responses. Rat pups in the tanshinone IIA group had improved postural reflex as demonstrated by the increased proportion of those that got a score 0 and reduced numbers with scores 1 and 2 (p Ͻ 0.05). Despite the improved functions, the performance of tanshinone IIA-treated pups remained inferior to that of sham-operated pups (p Ͻ 0.05). Similar results were observed when these scores were compared using the Mann Whitney U test.
Body temperature. At 4 h after hypoxia, the rectal temperatures of the sham-operated, vehicle-treated, and tanshinone IIA-treated animals were not different (35.7 Ϯ 0.30, 35.6 Ϯ There were no differences in the daily rectal temperatures between the three groups at all time points measured. Plasma ORAC. The ORAC was significantly higher in the plasma of animals that were treated with tanshinone IIA (p Ͻ 0.05) when compared with that of the vehicle-treated animals (Fig. 5) .
Effects of tanshinone IIA on viability of C17.2 neural progenitor cells. After seeding overnight, C17.2 cells grew to a monolayer, and most of them exhibited a flattened, elongated, fibroblast-like morphology (Fig. 6A ). After treatment with AAPH for 8 h, which induced oxidative damages to these cells, most of the cells lost their normal fibroblast-like morphology and appeared round in shape. Many of them were detached from their neighboring cells (Fig. 6B) . MTT assay showed that the viability of the C17.2 cells was dropped to 38 Ϯ 0.09% of the normal control (Fig. 6D) . Tanshinone IIA increased the viability of AAPH-treated cells in a dose-dependent manner at the range of 0.02-0.1 g/mL (Fig. 6D) , with its effect leveling off at the concentration of 0.2 g/mL. The cell morphology partially recovered in the presence of tanshinone IIA, and many cells appeared normal in shape with flat and extended cytoplasm (Fig. 6C) .
Effects of tanshinone IIA on mitochondrial integrity. In control untreated C17.2 cells (Fig. 7) , the majority of the cell population had intact mitochondria (R1, red fluorescence aggregates), with a low proportion of early apoptotic (R2) and apoptotic (R3, green fluorescence monomers) cells. The treatment with AAPH increased the total apoptotic cells (p ϭ 0.02), and similar trends were demonstrated in the R2 (p ϭ 0.16) and R3 (p ϭ 0.06) populations, compared with the control cultures. The presence of tanshinone IIA significantly decreased early apoptosis (R2, p ϭ 0.03), and a trend was observed in the proportion of total apoptotic cells (R2 ϩ R3, p ϭ 0.09).
DISCUSSION
The rat model of hypoxia-ischemia brain injury induced at day 7 of postnatal age was established by Levine (13) and modified by Rice et al. (14) . At this stage of development, the rat brain is histologically similar to that of a 32-to 34-wkgestation human infant. The neuropathologic damages observed in these animals are in good agreement with their behavioral deficits (2) . Various drugs, such as 21-aminosteroid Tirilazad mesylate (U-74006F) (15) , platelet-activating factor antagonist WEB (15) , erythropoietin (16) , and a herbal compound huperzine A (17), have been used in this model with some degree of success in reducing brain damage. A recent trial has demonstrated that moderate hypothermia treatment 
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TANSHINONE IIA NEUROPROTECTIVE EFFECT improved the most serious outcomes (death and severe motor scores) in human neonatal encephalopathy (18) .
In the present study, rat pups were subjected to right common artery occlusion combined with systemic hypoxia. We observed a reproducible pattern of brain injury, in terms of brain weight, histopathology, and number of sensorimotor neurons, in the ipsilateral but not the contralateral hemispheres. The neural damage was persistent at 3 wk after surgery and was translated to a compromised response to the postural reflex challenge. To investigate the protective effects of tanshinone IIA on this animal model, we adopted a pretreatment protocol as reported by several research teams (19 -21) . Our data showed that rat pups that were treated with tanshinone IIA 2 d before the induction of ischemia hypoxia for 16 d had marked recoveries in the ipsilateral hemispheres in all studied parameters. More significant, these animals scored better in the functional test, compared with the vehicle-treated group. To our knowledge, these data provided the first evidence that tanshinone IIA could confer marked histopathologic and behavioral protection against neonatal hypoxia-ischemia brain injury in vivo. Our data are in line with those of Lam et al. (22) , who demonstrated that tanshinone IIA at 16 mg/kg had the ability to reduce neuronal damage in an adult mouse model subjected to transient focal cerebral ischemia. One limitation of our model is that pretreating hypoxia-ischemia patients is unlikely to be possible in a clinical setting. Another concern is the lack of information on the pharmacokinetics of tanshinone IIA and its metabolites on neonatal rats. Lam et al. (22) reported that in brain tissues of adult mice, the level of tanshinone IIA peaked at 60 min and slowly declined to~50% after 5-6 h. Considering the effectiveness of tanshinone IIA on neuroprotection, issues on the timing of administration and therapeutic dose deserve further investigation.
Our findings raise the question as to how tanshinone IIA protects the brain from hypoxia-ischemia brain injury. Several protective mechanisms have been proposed. Studies in the hypoxia-ischemia model showed that some cholinesterase inhibitors such as HupA and donepezil had neuroprotective effects (17, 23) . Tanshinone IIA is an AchE inhibitor that has the potential to penetrate the blood-brain barrier (7). Lam et al. (22) reported that tanshinone IIA can readily penetrate the brain, reaching a peak concentration 60 min after i.p. injection to adult mice. In neonatal rats, excessive glutamate release during and after a hypoxia-ischemia insult might activate N-methyl-D-aspartate channel receptors, leading to further influx of calcium into cells, thus inducing neuronal death (24, 25) . Tanshinone IIA has been demonstrated to reduce glutamateinduced cytotoxicity by antagonizing cerebral NMDA receptors (6, 26) . Changes in body temperature are known to modulate neuronal damage in animal experiments and in clinical trials (27) . Hypothermia might suppress the release of excitotoxins, nitric oxide, and free radicals during reperfusion (28, 29) . In line with another report (11) , we demonstrated changes in body temperature with increasing postnatal age of the animals. We did not detect significant changes in the rectal temperatures of the three groups at 4 and 24 h after hypoxia, indicating that the neuroprotective effect of tanshinone IIA was possibly not mediated by hypothermia. However, one has to take into consideration that rectal temperature measurements, although correlating well with brain temperatures (30,31), might not be sensitive enough to detect small differences of the latter (29) . In addition, the animals were actively warmed in the incubator before rectal temperature measurement, and there is the possibility that this procedure might have masked a mild decrease in body temperature induced by the treatment. Oxygen radicals are markedly produced after a hypoxic-ischemic insult. Several lines of evidence have shown that tanshinone IIA can reverse the abnormalities induced by free radical injury as previously described by our laboratory and other researchers (26, 32) . It could also protect the mitochondrial membrane from ischemia-reperfusion injuries and lipid peroxidation (33) . In this study, we demonstrated that tanshinone IIA significantly improved the antioxidant capacity in rat plasma and protected the C17.2 progenitors against AAPH-induced cell death. We further confirmed that tanshinone IIA exerted a protective effect on mitochondrial membrane potential and decreased cell death secondary to oxidative stress.
The contribution of tanshinone IIA-induced antioxidant capacity to the protection against brain damage in our model remains to be investigated further. Our data and other evidence have shown an effective neuroprotective action by tanshinone IIA, possibly mediated by multiple pathways in hypoxicischemic neonatal animals. To date, the applications of neuroprotective agents, including tanshinone IIA, have not achieved total recovery of the damaged brain in various animal models. It thus is important to investigate the mechanism of each agent and the possibility of an integrated treatment strategy in maximizing the outcome. The present study suggests that pretreatment with tanshinone IIA is partially protective for hypoxiaischemia in the immature rat. As the treatment protocol spanned a very wide period before and after the hypoxicischemic insult, it is uncertain which treatment times were optimal for protection or whether rescue treatment is equally effective. We have confirmed that tanshinone IIA has antioxidant effects that may be beneficial, although other potentially relevant pathways might be involved. This study, however, did not purposefully evaluate whether brain cooling secondary to the treatment may have contributed to neuroprotection. Further studies are required to address these issues to verify the clinical potential of tanshinone IIA in helping to alleviate brain damage.
